Human VEGF-C DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human VEGF-C DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: VEGFC

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human VEGF-C DuoSet ELISA, 15 Plate

• Flt4 ligand
• Flt4-L
• vascular endothelial growth factor C
• Vascular endothelial growth factor-related protein
• VEGFC
• VEGF-C
• VRPFLT4 ligand DHM

Background

Vascular endothelial growth factor C (VEGF-C) is a homodimeric ligand of VEGF R3/Flt-4 and is synthesized with N- and C-terminal propeptides. Fully processed VEGF-C containing only the VEGF homology domain can additionally bind and activate VEGF R2/KDR/Flk-1. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis. Both the ligand and receptor are usually co-expressed at sites of lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, neoangiogenesis, and vessel sprouting, resulting in enhanced lymph flow and metastasis to regional lymph nodes.

Publications for VEGF-C (DY752B)(13)

Publications using DY752B

• Shams, S;Stilhano, RS;Silva, EA; Harnessing EGLN1 Gene Editing to Amplify HIF-1 alpha and Enhance Human Angiogenic Response bioRxiv : the preprint server for biology 2023-05-30 [PMID: 37398294] (Human)
• J Jiang, X Cong, S Alageel, U Dornseifer, AF Schilling, E Hadjipanay, HG Machens, P Moog In Vitro Comparison of Lymphangiogenic Potential of Hypoxia Preconditioned Serum (HPS) and Platelet-Rich Plasma (PRP) International Journal of Molecular Sciences, 2023-01-19;24(3):. 2023-01-19 [PMID: 36768283] (Human)
• Y Ding, L Oliveira-F, E Vettorazzi, K Legler, K Milde-Lang, L Woelber, A Jaeger, K Prieske, V Mueller, B Schmalfeld, S Kuerti VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients PLoS ONE, 2022-06-10;17(6):e0269680. 2022-06-10 [PMID: 35687576] (Human)
• JP Lapuente, A Blázquez-M, J Marco-Brua, G Gómez, P Desportes, J Sanz, P Fernández, M García-Gil, F Bermejo, JV San Martín, A Algaba, JC De Gregori, D Lapuente, A De Gregori, B Lapuente, MV Andrés, A Anel Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM) Biomolecules, 2022-03-31;12(4):. 2022-03-31 [PMID: 35454123] (Human)
• L Cristinzia, R Poto, G Criscuolo, AL Ferrara, MR Galdiero, L Modestino, S Loffredo, A de Paulis, G Marone, G Spadaro, G Varricchi IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors Cells, 2021-01-12;10(1):. 2021-01-12 [PMID: 33445787] (Human)
• G Varricchi, S Loffredo, L Bencivenga, AL Ferrara, G Gambino, N Ferrara, A de Paulis, G Marone, G Rengo Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A2 in Ischemic and Non-Ischemic Heart Failure J Clin Med, 2020-06-19;9(6):. 2020-06-19 [PMID: 32575548] (Human)
• G Varricchi, S Loffredo, F Borriello, A Pecoraro, F Rivellese, A Genovese, G Spadaro, G Marone Superantigenic Activation of Human Cardiac Mast Cells Int J Mol Sci, 2019-04-12;20(8):. 2019-04-12 [PMID: 31013832] (Human)
• PD Ndiaye, M Dufies, S Giuliano, L Douguet, R Grépin, J Durivault, P Lenormand, N Glisse, J Mintcheva, V Vouret-Cra, B Mograbi, M Wurmser, D Ambrosetti, N Rioux-Lecl, P Maire, G Pagès VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness Theranostics, 2019-01-21;9(3):661-675. 2019-01-21 [PMID: 30809300] (Human)
• J Bourland, J Fradette, FA Auger Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development Sci Rep, 2018-09-04;8(1):13191. 2018-09-04 [PMID: 30181613] (Human)
• M Lupu-Plesu, A Claren, S Martial, PD N'Diaye, K Lebrigand, N Pons, D Ambrosetti, I Peyrottes, J Feuillade, J Hérault, M Dufies, J Doyen, G Pagès Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma Oncogenesis, 2017-07-03;6(7):e354. 2017-07-03 [PMID: 28671677] (Human)
• Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, Babu S Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect, 2016-10-04;74(1):10-21. 2016-10-04 [PMID: 27717783] (Human)
• Kumar N, Banurekha V, Nair D, Babu S Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE, 2016-01-04;11(1):e0146318. 2016-01-04 [PMID: 26727122] (Human)
• Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec J, Negrier S, Simonnet H, Pages G The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res, 2013-12-12;74(3):873-83. 2013-12-12 [PMID: 24335961] (Human)

FAQs for VEGF-C (DY752B). (Showing 1 - 2 of 2 FAQs).

1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
   • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.
2. wondering what the difference is between your quantikine and duo set elisas?
   • Usually the duosets do not have the entire kit such as plates and buffers, whereas the other kits are complete.

Bioinformatics

• Gene Symbol: VEGFC